<SEC-DOCUMENT>0001140361-22-020820.txt : 20220526
<SEC-HEADER>0001140361-22-020820.hdr.sgml : 20220526
<ACCEPTANCE-DATETIME>20220526170017
ACCESSION NUMBER:		0001140361-22-020820
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220526
DATE AS OF CHANGE:		20220526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		22971072

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ny20004344x1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 8.1.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="ny20004344x1_defa14a_00-regcov_pg1"><!--Anchor--></a><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Washington, D.C. 20549</font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">SCHEDULE 14A</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; text-align: center;">Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Filed by the Registrant &#x2612;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Filed by a Party other than the Registrant <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Check the appropriate box:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt;">&#8201;<font style="font-size: 10pt;">&#x2610;</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; text-align: left;"><font style="font-size: 10pt;">Preliminary Proxy Statement</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt;">&#8201;<font style="font-size: 10pt;">&#x2610;</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; text-align: left;"><font style="font-size: 10pt; font-weight: bold;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt;">&#8201;<font style="font-size: 10pt;">&#x2610;</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; text-align: left;"><font style="font-size: 10pt;">Definitive Proxy Statement</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#x2612;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Definitive Additional Materials</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt;">&#8201;<font style="font-size: 10pt;">&#x2610;</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; text-align: left;"><font style="font-size: 10pt;">Soliciting Material under </font><font style="font-size: 10pt;">&#167;</font><font style="font-size: 10pt;">240.14a-12</font></div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">BIOCRYST PHARMACEUTICALS, INC.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt; font-weight: normal;">(Name of Registrant as Specified In Its Charter)</font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt; font-weight: normal;">&#8195;</font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt; font-weight: normal;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</font></div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td colspan="4" style="width: 100%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payment of Filing Fee (Check all boxes that apply):</div></td></tr><tr><td style="width: 4.44%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 93.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No fee required.</div></td></tr><tr><td style="width: 4.44%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 93.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fee paid previously with preliminary materials.</div></td></tr><tr><td style="width: 4.44%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 93.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</div></td></tr></table></div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20004344x1_defa14a_00-regcov_pg2"><!--Anchor--></a><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 76px; width: 188px;" src="logo_biocryst2a.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">BIOCRYST PHARMACEUTICALS, INC. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">4505 Emperor Blvd., Suite 200 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Durham, North Carolina 27703<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 5.5pt; margin-left: 0pt; text-align: left;">To the Stockholders of BioCryst Pharmaceuticals, Inc.:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The 2022 Annual Meeting of Stockholders (the &#8220;Meeting&#8221;) of BioCryst Pharmaceuticals, Inc. (&#8220;BioCryst&#8221; or the &#8220;Company&#8221;) will be held on June&#160;7, 2022 at 10:00 a.m. Eastern Time at our Company headquarters at 4505 Emperor Blvd., Suite 200, Durham, NC 27703. As previously disclosed in our Proxy Statement, the record date for determining the Company&#8217;s stockholders entitled to vote at the Meeting has been fixed as of the close of business on April&#160;11, 2022. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our Proxy Statement requests that the Company&#8217;s stockholders consider and vote upon a number of proposals, including a proposal to approve an amendment and restatement to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated, the &#8220;Stock Incentive Plan&#8221;), increasing the number of shares of the Company&#8217;s common stock (&#8220;Common Stock&#8221;) available for issuance under the Stock Incentive Plan by 8,000,000 shares (&#8220;Proposal 4&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Glass Lewis &amp; Co. Inc. has recommended a vote <font style="font-weight: bold;"><u>FOR</u></font> Proposal 4. Another advisory firm, Institutional Shareholder Services (&#8220;ISS&#8221;), found that the Stock Incentive Plan&#8217;s estimated costs, the plan features, and our equity grant practices resulted in a favorable score, but recommended against Proposal 4 based on its dilution calculation. Although we respect the ISS approach, please consider the following points as you evaluate Proposal 4:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic; font-weight: bold;">We are in a highly competitive marketplace for biotech talent, and without the ability to offer competitive </font><font style="font-style: italic; font-weight: bold;">equity grants to attract and retain our talent, we may lose, or fail to attract, key employees, which could </font><font style="font-style: italic; font-weight: bold;">impair our ability to grow and harm stockholder value.</font> The Company added approximately 126 employees in 2021, increasing its net employee headcount at December&#160;31, 2021 by approximately 53.4% compared to December&#160;31, 2020, in connection with the commercial launch of ORLADEYO&#174; (berotralstat) in the United States, Japan, and Europe and the advancement of other pipeline molecules. The Company continues to add talent in 2022 as it supports the further growth of ORLADEYO around the world, and the advancement of additional product candidates.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic; font-weight: bold;">The Company has created a culture of ownership that aligns employees with stockholders by offering </font><font style="font-style: italic; font-weight: bold;">every employee equity as an incentive to join the Company and annually at the end of each year.</font> Despite the highly competitive biotech market, BioCryst has experienced very low turnover, and we believe this is in part due to the long-term retentive nature of equity incentives and this ownership culture.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic; font-weight: bold;">Our ability to attract and retain top talent has been critical to driving the strong launch of ORLADEYO </font><font style="font-style: italic; font-weight: bold;">and strong overall performance of the Company, and is vital to the continued success of the ORLADEYO </font><font style="font-style: italic; font-weight: bold;">launch.</font> In 2021, ORLADEYO generated approximately $122&#160;million in net revenue. In 2022, the Company expects ORLADEYO net revenue to double to no less than $250&#160;million, with peak sales of $1&#160;billion. To achieve these goals, the Company must retain and attract top talent, and equity is critical to support this continued growth.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic; font-weight: bold;">The Company has demonstrated its focus on limiting potential dilution to current stockholders.</font> Over the past two years, the Company has raised approximately $550&#160;million in cash through mechanisms such as royalty and debt financings as alternatives to equity financings that would have been highly dilutive to stockholders. There were many factors that made these alternative financing approaches attractive, including the ability to bring this cash into the Company without additional equity dilution. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic; font-weight: bold;">The ISS dilution calculation includes BioCryst employees&#8217; outstanding unexercised stock options and </font><font style="font-style: italic; font-weight: bold;">restricted stock units, but does not account for the positive impact of this long-term employee ownership </font><font style="font-style: italic; font-weight: bold;">and its alignment with stockholders. </font>The Company&#8217;s employee stock options have a 10-year term, and the current average holding period for our employees is approximately seven years. This long-term employee ownership illustrates the positive impact of equity as a retention tool, which aligns with stockholders.</div></td></tr></table></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20004344x1_defa14a_00-regcov_pg3"><!--Anchor--></a><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As of May&#160;23, 2022, the Company had a total of 185,623,300 shares of Common Stock outstanding. The potential share dilution from the 8,000,000 additional shares to be reserved for issuance under the Stock Incentive Plan, for which stockholder approval is being requested, is 4.3% of the Company's outstanding shares of Common Stock as of such date. Approximately 33% of shares reserved for awards already granted under our equity plans are underwater as of May&#160;23, 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of May&#160;23, 2022</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total number of shares of Common Stock subject to outstanding stock options <font style="padding-left: 2.63pt;"></font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.47%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">32,388,332</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average exercise price per share of outstanding stock options <font style="padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.47%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">$7.91</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining term of outstanding stock options (in years)<font style="padding-left: 4.42pt;"></font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.47%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">7.26</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total number of shares of Common Stock subject to outstanding full value awards <font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.47%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">2,444,550</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total number of shares of Common Stock available for grant under Company equity plans<font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.47%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">3,549,157</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Board Recommendation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our Board of Directors unanimously recommends that you vote <font style="font-weight: bold;"><u>FOR</u></font> the approval of the amended and restated Stock Incentive Plan described in Proposal 4.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Even if voting instructions for your proxy have already been given, you can change your vote at any time before the Meeting by giving new voting instructions as described in more detail in the Proxy Statement. Should you have any questions or need any assistance in submitting your proxy to vote your shares, please contact our proxy solicitor, Georgeson LLC, toll-free at 877-278-4774.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our Proxy Statement, including this Supplement, and our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 are available free of charge at www.proxyvote.com.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 9.5pt; margin-left: 0pt; text-align: left;">Cautionary Note Regarding Forward-Looking Statements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Supplement contains forward-looking statements, including statements regarding the Company&#8217;s plans and expectations for ORLADEYO. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company&#8217;s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the Company&#8217;s ability to successfully implement its commercialization plans for, and to commercialize, ORLADEYO, which could take longer or be more expensive than planned; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; and actual financial results may not be consistent with expectations, including that revenue may not be within management's expected ranges. Please refer to the documents the Company files periodically with the Securities and Exchange Commission, specifically the Company&#8217;s most recent Annual Report on Form 10-K, Quarterly Reports on Form&#160;10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause actual results to differ materially from those contained in the Company&#8217;s projections and forward-looking statements.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BY ORDER OF THE BOARD OF DIRECTORS</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alane P. Barnes, Corporate Secretary</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Durham, North Carolina<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 26, 2022</div></div></div></div>
<!--End Page 3-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_biocryst2a.jpg
<TEXT>
begin 644 logo_biocryst2a.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M444 %%%% !1110!_,%\?O^2[_&O_ +*W\2/_ %,=9K]N/V"O^37_  %_U_\
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MC2:3:YDL5BL-6:>ZO13L]K^Z?T04UF5%9W941%+.[$*JJH)9F8D!54 DDD
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M_$3Q9?2NUWJ5Q-)8Z/8S74T]CX7\(:(CM8>&?"VE-<O!HOAO1;>VTZQC8B*
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M_P"")W[07P?_ &6?^"G'[,_QX^/?C2V^'OPF\"_\+F_X2OQA>:7KVM6VD?\
M"3_L_?%;P;H7F:9X9TK6]<N?[0\2^(=&TM/L.F7/DR7JW%SY-G%<7$7]^O\
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M+/5-*OK2^M795+P3HQ4$X'\$G_!UY^VS+\2_VC_AM^Q)X1U>5_!_[.NCVWQ
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M8_'6@2P^*=6MKH/]GF?X?_#75FM+S3KB!S]L^*'A[5[::&XT==_];7_!7/\
M9H\8_M??\$X/VK?@!\/+=K_Q[XL\ :=XA\%Z-'&)+CQ)XI^%WC/PQ\6-!\)V
M6Z[L88M1\7:GX'MO#.FW-U=16-K?ZK;W-^)+.*>)^_\ ^"<O['>@_L&_L9?
MW]F32&L[O5_ _A5+[XA:]9JC)XH^*7BFXF\2?$374N?LUK<W6FR>*-2O]/\
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M (Q\-SA(VNM""V7AS5O#_C#6;5Y0BV_P[U[Q>EZ S6,EP8ITA_G?_P""C?\
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M:#9)J=]^SIXBM-0345\4^']+G@O(M5^"MQ>@'4-*N[:\M_ :RR6&H6]SX#N
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9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
